Nadroparin LMWH

LMF CY216 - LMF CY 216 - LMF CY-216 - CY216 - CY-216 - CY 216 - Fraxiparine - Fraxiparin - Nadroparine      

pdf
pathology Demonstrated benefit and harm k      
acute coronary syndrome

versus UFH

No demonstrated result for efficacy

2 trialsmeta-analysis
pulmonary embolism

versus unfractioned heparin

No demonstrated result for efficacy

3 trialsmeta-analysis
superficial thrombophlebitis

versus antithrombotics

No demonstrated result for efficacy

3 trialsmeta-analysis
thrombosis prevention

versus placebo or control

No demonstrated result for efficacy

9 trialsmeta-analysis
thrombosis prevention

versus placebo or no treatment

No demonstrated result for efficacy

2 trialsmeta-analysis
thrombosis prevention

versus

No demonstrated result for efficacy

6 trialsmeta-analysis
venous thrombosis

versus anticoagulant

No demonstrated result for efficacy

1 trialmeta-analysis
venous thrombosis

versus oral anticoagulant

No demonstrated result for efficacy

2 trialsmeta-analysis
venous thrombosis

versus

No demonstrated result for efficacy

3 trialsmeta-analysis
venous thrombosis

versus twice daily LMWH

No demonstrated result for efficacy

1 trialmeta-analysis